Europe
Pharming Group N.V. announces that, following receipt of the Dutch investigating centre’s ethics committee approval, it is commencing a clinical study of the effects of its recombinant human C1 esterase inhibitor (rhC1INH), RUCONEST®, in patients with pre-eclampsia.
Servier and Galapagos NV completed recruitment for their ROCCELLA Phase 2 trial with GLPG1972/S201086, ahead of schedule.
Sugar.IQ Insights Viewed as Helpful and Enable Users to Avoid Diabetes-Related Events up to Four Hours in Advance
“Over the past few years there has been a good amount of information presented at ADA. This year though, with all of the data presented, this was the most exciting year,” Todd Hobbs, U.S. chief medical officer of Novo Nordisk, told BioSpace in an exclusive interview.
“We are honored to join with The Bill & Melinda Gates Foundation to fight tuberculosis, one of the world’s most deadly infectious diseases,” stated Werner Lanthaler, Evotec’s chief executive officer.
The FAST Advisory Program gives chosen entrepreneurs intensive team review and coaching to fine-tune their business model, product development plans and to build a compelling commercialization strategy.
The agreement is the outcome of preclinical research on novel CD38 targeting concepts conducted by Genmab.
Denis Rebrikov indicates he plans to ask for approval from three government agencies, including Russia’s health ministry. He told Nature that could take anywhere from one month to two years.
Evotec SE announced that the company has entered into a five-year partnership with the Bill & Melinda Gates Foundation to discover new treatment regimens that better address tuberculosis (“TB”), a severe global health burden and one of the leading causes of death due to infectious diseases worldwide.
To enable upcoming regulatory filings, Medtronic plc made public its partnership with KARL STORZ SE & Co. KG, a pioneer in the field of endoscopic imaging.
PRESS RELEASES